Pages that link to "Q38447382"
The following pages link to Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. (Q38447382):
Displaying 50 items.
- The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells (Q33376263) (← links)
- Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission (Q33750753) (← links)
- Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity (Q33766467) (← links)
- Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate (Q33861815) (← links)
- Targeted treatment of chronic myeloid leukemia: role of imatinib. (Q33915973) (← links)
- The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by Imatinib (Q34369606) (← links)
- Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase (Q34443523) (← links)
- Recent advances in the understanding of mastocytosis: the role of KIT mutations. (Q34635424) (← links)
- Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy (Q35667438) (← links)
- Successful application of a direct detection slide-based sequential phenotype/genotype assay using archived bone marrow smears and paraffin embedded tissue sections (Q36103451) (← links)
- Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case (Q37280862) (← links)
- Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. (Q37360559) (← links)
- Update on cytogenetic and molecular changes in myelodysplastic syndromes (Q37923939) (← links)
- Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report (Q38685696) (← links)
- Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia (Q39004368) (← links)
- How I treat CML blast crisis (Q39609275) (← links)
- A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML. (Q42665076) (← links)
- Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. (Q43078241) (← links)
- Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. (Q43266877) (← links)
- Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML). (Q43291755) (← links)
- Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance? (Q45112330) (← links)
- Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib (Q45201448) (← links)
- Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha (Q45206587) (← links)
- Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib. (Q45991055) (← links)
- t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia (Q46074323) (← links)
- Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform (Q46179041) (← links)
- Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors (Q46192237) (← links)
- Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia (Q46265415) (← links)
- Induction of centrosome and chromosome aberrations by imatinib in vitro (Q46577685) (← links)
- Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study (Q46616933) (← links)
- Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. (Q46685541) (← links)
- Hematological side effects of tyrosine kinase inhibition using imatinib (Q46900475) (← links)
- Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. (Q46947501) (← links)
- Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome (Q46958489) (← links)
- Comparative study of cytogenetic response evaluated by conventional banding analysis and fluorescence in situ hybridization in chronic myeloid leukemia patients during tyrosine kinase inhibitor treatment (Q49968961) (← links)
- Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update (Q49993294) (← links)
- Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy (Q50884247) (← links)
- Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia (Q53264656) (← links)
- Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia. (Q53346102) (← links)
- Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation. (Q54278842) (← links)
- Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy. (Q54561399) (← links)
- Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second‐line agents, and beyond (Q54607049) (← links)
- Chronic Myeloid Leukemia: Beyond BCR-ABL1 (Q58102326) (← links)
- Characterization of Ph-negative abnormal clones emerging during imatinib therapy (Q58449075) (← links)
- Cytogenetic evolution patterns in CML post-SCT (Q79520861) (← links)
- Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia (Q83524633) (← links)
- Myelodysplastic Syndrome with Ph Negative Monosomy 7 Chromosome following Transient Bone Marrow Dysplasia during Imatinib Treatment for Chronic Myeloid Leukemia (Q83525115) (← links)
- Sequential chronic myelogenous leukemia, B-lineage lymphoma and erythroleukemia with monosomy 7 over 10 years (Q85013847) (← links)
- Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia (Q90680132) (← links)
- [The significance of non-Ph chromosome in chronic myelogenous leukemia] (Q99563212) (← links)